Adverse Events Associated With Nickel Allergy in Patients Undergoing Percutaneous Atrial Septal Defect or Patent Foramen Ovale Closure  by Wertman, Brett et al.
RT
(
a
e
i
o
e
(
(
r
a
p
M
T
c
d
T
g
p
m
w
p
9
a
d
p
i
n
a
b
t
t
T
p
a
d
s
a
M
fi
s
c
t
r
o
t
T
c
d
Journal of the American College of Cardiology Vol. 47, No. 6, 2006
© 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00
PCORRESPONDENCE
esearch Correspondence
Adverse Events Associated With Nickel Allergy in Patients Undergoing Percutaneous
ublished by Elsevier Inc.Atrial Septal Defect or Patent Foramen Ovale Closure
w
p
t
c
t
r
t
o
p
n
n
t
i
T
m
h
f
g
o
o
M
a
t
w
g
A
f
o
i
t
m
e
t
p
A
a
p
T
a
C
C
N
P
Co the Editor: Percutaneous closure of patent foramen ovale
PFO) or atrial septal defect (ASD) interatrial communications is
relatively safe procedure with occasional side effects. Transcath-
ter closure of atrial septal communication has been reported to
mprove migraine headache with or without aura (MHA) in 60%
f patients (1), but paradoxically, there are reports of patients who
xperience an increase in MHA for several weeks post-procedure
2,3). Nickel hypersensitivity occurs in up to 15% of the population
4) and has been associated with side effects in two patients who
eceived nitinol implantable devices (5). This analysis addresses the
ssociation of nickel allergy and post-closure adverse events in 37
atients who had ASD or PFO closure with an Amplatzer (AGA
edical, Golden Valley, Minnesota) device composed of nitinol.
The patients received nickel allergy patch testing with the
RUE skin test (6) either before or after closure of the interatrial
ommunication. Incidence of post-closure palpitations and chest
iscomfort was assessed by telephone interview and clinic visits.
he MHA frequency and severity was evaluated using the Mi-
raine Disability Assessment (MIDAS) questionnaire (7). All
atients underwent transesophageal echocardiography at one
onth post-procedure. With the exception of one patient taking
arfarin for a hypercoagulable state, all patients received anti-
latelet therapy with aspirin indefinitely and clopidogrel for 30 to
0 days post-procedure.
Between 2001 and 2005, there were 108 patients who received
PFO closure device and 42 patients who received an ASD closure
evice. Of the 150 patients, 62 (41%) experienced chest pain,
alpitations, or increased MHA. Nickel patch testing was available
n 37 patients. There were seven patients (5%) who noted
ew-onset MHA or increased frequency and severity of MHA or
ura post-procedure. The average MIDAS scores of these patients
efore and after the procedure were 0 and 41 37, respectively. Of
he seven patients, six were tested for nickel allergy, and four of
hese patients (67%) had a positive nickel skin test result (Table 1).
his finding occurred more frequently with ASD devices com-
ared with PFO devices (12% vs. 2%, p  0.02) (Table 2).
New-onset or worsening MHA was associated with nickel
llergy (p  0.035) (Table 1). When adverse events (chest
iscomfort, palpitations, and MHA) were combined, there was a
ignificant association with nickel allergy (p  0.028). The
ssociation was strongest (p  0.005) with chest discomfort and
HA.
Of the six patients in whom new or increased MHA developed,
ve patients had headaches that developed within one week of
topping clopidogrel. These patients were treated by re-initiating
lopidogrel at 75 mg/day. Although the MHAs had been persis-
ent for three to five days, all patients reported almost complete
elief of their symptoms within a few hours of taking the first dose
f clopidogrel. Clopidogrel was then stopped after one month in
wo patients, and both had recurrence of MHA within five days.
he symptoms were abolished again within hours of restarting
lopidogrel in both women. The sixth patient developed pericar-
itis with effusion and atrial fibrillation as well as MHA within one Meek of the implantation. He was treated with a tapering dose of
rednisone. Because he had a hypercoagulable condition, he was
reated with warfarin and therefore had not been placed on
lopidogrel before or after the procedure. After seven months and
wo courses of prednisone, the chest pain and palpitations have
esolved and the headaches have improved.
The most important observation of this study was that 67% of
he patients who had new onset or increased frequency and severity
f MHA tested positive for nickel hypersensitivity. The two
atients who also experienced symptoms but were not allergic to
ickel had large ASD devices (38 mm). The sample size is small;
evertheless, these observations raise intriguing hypotheses.
One possible mechanism to explain the new onset or exacerba-
ion of MHA is that a local inflammatory reaction to the
mplanted device results in the formation of platelet adhesions.
hese substances could then embolize to the brain, causing
icroinfarcts and MHA. An observation that lends support to this
ypothesis is that five of the patients noted a marked increase in
requency of MHA shortly after discontinuing clopidogrel, sug-
esting that the pharmacologic suppression of platelet aggregation
n the implanted device may be preventing embolization. One
ther report has documented the benefit of clopidogrel in reducing
HA after nitinol device implantation (8). All five patients noted
n improvement in MHA after re-starting clopidogrel. However,
here was no evidence of abnormal MRI lesions in the two cases
ith the most severe MHA. In addition, follow-up transesopha-
eal echocardiography did not show any thrombus on any of these
mplatzer devices. Therefore, there is no evidence for thrombus
ormation as the etiology of these neurologic symptoms.
An alternative mechanism to explain new onset or exacerbation
f MHA is that a localized reaction around the device releases
nflammatory mediators into the left atrium, which then travel to
he cerebral circulation and induce MHA. Presumably the inflam-
ation is greater if the patient is sensitive to nickel, but an
xaggerated response may occur without nickel allergy and produce
he same symptom complex, especially if a large device is im-
lanted. This may explain why MHA are more likely to occur with
SD closure devices. This hypothesis opens research avenues to
ssess the effect of chemokines or other inflammatory proteins as
rimary triggers for MHAs in patients with or without implanted
able 1. Incidence of Post-Procedural Complications
s a Function of the Presence or Absence of Nickel Allergy
Nickel
Test 
n  10 (%)
Nickel
Test 
n  27 (%)
p
Value
hest discomfort, palpitations,
or MHA/aura
9 (90) 13 (48) 0.028
hest discomfort or MHA/aura 6 (60) 3 (11) 0.005
ew or worsening MHA/aura 4 (40) 2 (7) 0.035
alpitations 5 (50) 11 (41) 0.7
hest discomfort 3 (30) 2 (7) 0.1HA  migraine headache with or without aura.
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March 21, 2006:1226–38evices. This concept is consistent with the observation that
losure of PFO or ASD leads to a dramatic reduction or abolition
f MHAs in 75% of patients (1). The observation that these
atients responded dramatically and rapidly to administration of
lopidogrel suggests that this drug may be acting as an anti-
nflammatory agent, either to decrease the release of the trigger
hemicals from the inflammatory site in the left atrium or by acting
n nociceptive neural adenosine receptors to inhibit the migrain-
us response to inflammatory byproducts.
The initial recognition of nickel hypersensitivity as a potential
roblem occurred with our sentinel case. Subsequently, an attempt
as made to contact previous patients that we had treated. All
rospective patients thereafter were screened for nickel allergy.
his selection bias captured all of the patients who complained of
n adverse event, but the study population does not represent all of
he patients without symptoms who might have a positive nickel
llergy skin test result. This report of a 27% (10 of the 37) positive
ickel allergy rate is therefore likely exaggerated.
In conclusion, new onset or increased frequency and severity of
HA after interatrial communication closure is associated with
ickel hypersensitivity and large ASD devices. This phenomenon
ay be related to byproducts of an exaggerated inflammatory
esponse. These events may persist for three to six months, but all
able 2. Presence of MHA, Palpitations, or Chest Discomfort
s a Function of Device Type
PFO Closure
Device
n  108 (%)
ASD Closure
Device
n  42 (%)
p
Value
HA 2 (2) 5 (12) 0.02
alpitations 26 (24) 14 (33) 0.3
hest discomfort 13 (12) 2 (5) 0.2
SD  atrial septal defect; MHA  migraine headache with or without aura; PFO
patent foramen ovale.Prospective Aortic Screening in M
hat these two aneurysmal diseases might be associated and that
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nd PFO closure in patients with nickel allergy is warranted.
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closure migraines. Catheter Cardiovasc Interv 2004;63:255.en With Coronary Aneurysmso the Editor: In older men, abdominal aortic aneurysm (AAA)
s a frequent cause of morbidity and mortality. The prevalence of
symptomatic AAA is within the range of 5% to 7% in men 65
ears old (1,2). Ultrasonography is the method of choice for the
etection of AAA and may allow a significant reduction in
neurysm-related death (1). However, despite these positive re-
ults, systematic screening remains uncommon in usual practice
2). The yield of ultrasound detection of AAA would be increased
y the introduction of more selective screening, but until now there
as been no formal evaluation of using screening criteria other than
ender or age.
Coronary angiography is widely used for the evaluation of
uspected coronary artery disease (CAD). We recently reported
hat coronary aneurysms (CA), which are found in 2% to 5% of
atients undergoing coronary angiography may share common
enetic susceptibility factors with AAA (3). Retrospective studies
lso suggest that CA and AAA may be associated (3,4). However,
prospective evaluation of the risk of AAA in patients with CA is
acking. We thus designed the present study to test the hypothesisatients who had CA identified at angiography may constitute a
roup at high risk of AAA in whom aortic screening would result
n a high diagnostic yield.
Male patients undergoing coronary angiography in our institu-
ion, and with angiographic evidence of CAD, were eligible for
nclusion immediately after the procedure. Our ethics committee
pproved the protocol, and all patients gave written informed
onsent. We excluded patients who underwent coronary angiog-
aphy before AAA surgical repair. A single investigator, unaware
f the clinical details of the patient, reviewed the angiograms. The
A group comprised patients with localized or diffuse coronary
ilation that exceeded the diameter of the angiographically appar-
ntly normal adjacent segments by a factor of 1.5 (5). For every
ase, one control without CA was randomly selected from the
ame population.
An ultrasound scan of the abdominal aorta was performed
ithin 24 h of coronary angiography by experienced ultrasonog-
aphers unaware of the group assignment of the patient. The
aximal anterior-posterior diameters of the suprarenal aorta just
pon the left renal artery ostium and the infrarenal aorta were
